Glycostem Chief Development Officer Volker Huppert is going to attend Cell 2023 meeting in London during 07/08 Nov 2023 as a key speaker.
Amanda van Vliet and Anna-Maria Georgoudaki will be attending CICON2023 20-23rd of September, and presenting 2 posters on Glycostem's latest developments in the field of NK cells for Cancer Immunotherapy and Combination Therapy.
poster #1 Superior cytotoxic signatures of cord blood stem cell-derived Natural Killer cell therapeutics identified with bulk and single-cell transcriptomics analysis.
poster #2 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies or innate cell engagers leads to potent ADCC through engagement of endogenous CD16.
Glycostem Senior Research Manager Anna-Maria Georgoudaki is going to present at the 2nd Cell Therapy Potency Assay Summit in Boston.
Date/Time: 1 June 2023, 16:00-16:30 EDT (GMT-4).
Presentation Title: Maintaining GMP Standards Across Cell Manufacture into Potency Assay Development to Follow a Licensed Approach
• Developing GMP standards for quantitatively testing potency and biological activity
• Setting the expectations of routine potency release testing to GMP standards
• Relating GMP testing and method to the mechanisms of action of the cell therapy
Glycostem Chief Development Officer Volker Huppert to host an online panel discussion 30th May as part of the Cell UK Series.
Glycostem Chief Scientific Officer Jan Spanholtz is going to participate and present at the Natural Killer Cell Online Symposium 2023 virtually.
Presentation title: GTA002/oNKord – The Beauty Of Being A Natural Killer
Date/Time: 24 May 2023, 08:50 - 09:10 EDT (UTC -4)
Panel Discussion: NK-Based Therapies: Development, Applications & Challenges
Date/Time: 24 May 2023, 10:30-11:00 EDT (UTC -4)
Glycostem Senior Research Manager Monica Raimo is going to join the 26th ASGCT Annual Meeting from 16-20 May, 2023 in Los Angeles. On Thursday 18 May she is going to have a poster presentation in the conference hall.